Abstract During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for
ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according …

Objective To evaluate clinical and laboratory effects of delaying ocrelizumab infusions
during the COVID-19 pandemics in people with multiple sclerosis (pwMS). Methods We …

Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus
disease 2019 (COVID-19) has killed hundreds of thousands of humans in a global …

In this observational study, 159 patients with multiple sclerosis received personalized dosing
of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when …

Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in
desperate need of a protection against SARS-CoV-2 infection. Methods In this study …

Background and purpose During the COVID‐19 pandemic, ocrelizumab administration was
frequently postponed because of a lack of safety information and to favour vaccination. The …

Background The COVID-19 epidemic raises important questions about the efficacy of
vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been …

Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune
responses after severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) …

Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …